Cytomedix, Inc. (NYSE Alternext US: GTF) is a biotechnology company focused on regenerative technologies in the areas of wound care, inflammation, and angiogenesis.

We develop, sell, and license regenerative biological therapies, including the AutoloGel™ System, a device for the production of platelet rich plasma (“PRP”) gel. The AutoloGel™ System is cleared by the Food and Drug Administration (“FDA”) for use on a variety of exuding wounds. Published, peer reviewed studies have concluded that AutoloGel™  provides very attractive healing outcomes and may reduce the overall cost of caring for chronic wounds. We are currently pursuing a multi-faceted strategy to penetrate the chronic wound market with the AutoloGel™ System.

We are also moving forward with the development of other product candidates in our pipeline. Most notably is our CT-112 product, an anti-inflammatory peptide, that has shown promise in pre-clinical testing, demonstrating efficacy, safety, and oral bio-availability, and for which we are currently preparing an Investigational New Drug (IND) application for the FDA.

Each of our products and product candidates addresses multi-billion dollar markets and possesses distinct competitive advantages over existing therapies. The technological platforms underpinning our products leverage the human body’s naturally-occurring proteins and other biological actors. Our technologies are protected by a growing list of families of granted and pending patents in the U.S. and internationally as well as proprietary methodologies and know-how.

Headquartered in Rockville, MD, we employ approximately 16 people, with scientific, clinical, sales, marketing, regulatory, and financial expertise.
© 2009 Cytomedix.  All Rights Reserved. Site Map | Terms & Conditions